Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

31 Jan 2021

Residential segregation, discriminatory practices impact outcomes of Black lung cancer patients

Structural racism thwarts a large proportion of black patients from receiving appropriate lung cancer care, resulting in worse outcomes and shorter lifespans than white patients with the disease, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.

29 Jan 2021

New approach to capture natural killer cells and harvest cancer-killing packets

Building on the promise of emerging therapies to deploy the body's "natural killer" immune cells to fight cancer, researchers at the University of Michigan Rogel Cancer Center and U-M College of Engineering have gone one step further.

28 Jan 2021

Genetic changes in tumors can help predict the efficacy of immunotherapy drugs

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumors which could be used to predict if immunotherapy drugs would be effective in individual patients.

28 Jan 2021

Missing surface protein allows small cell lung cancer cells to hide from immune defenses

Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body's key cancer defenses, a new study led by UT Southwestern researchers suggests.

25 Jan 2021

Researchers develop comprehensive framework to classify small-cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell.

22 Jan 2021

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC).

5 Jan 2021

Study uncovers why cancer patients with liver metastases have poor outcomes

Michael Green, M.D., Ph.D., noticed that when his patients had cancer that spread to the liver, they fared poorly – more so than when cancer spread to other parts of the body. Not only that, but transformative immunotherapy treatments had little impact for these patients.

4 Jan 2021

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020

Multisystem immune-related adverse events linked with improved survival from immunotherapy in NSCLC

The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival.

14 Dec 2020

New combination therapy has potential to treat aggressive cancers with common mutations

Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.

14 Dec 2020

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors.

1 Dec 2020

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute described a potential therapeutic anticancer vaccine that frees suppressed cancer-killing immune cells, enabling them to attack and destroy a tumor.

23 Nov 2020

New model can predict the risk of adverse side effects of cancer treatment

The risk of serious adverse effects on the blood status and bone marrow of patients during chemotherapy can be predicted by a model developed at Linköping University, Sweden.

12 Nov 2020

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Pre-Conference Programs.

11 Nov 2020

High dose radiation therapy linked to shorter survival times in NSCLC patients

A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway.

29 Oct 2020

Non Small Cell Lung Cancer News and Research

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

Residential segregation, discriminatory practices impact outcomes of Black lung cancer patients

New approach to capture natural killer cells and harvest cancer-killing packets

Genetic changes in tumors can help predict the efficacy of immunotherapy drugs

Missing surface protein allows small cell lung cancer cells to hide from immune defenses

Researchers develop comprehensive framework to classify small-cell lung cancer

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Study uncovers why cancer patients with liver metastases have poor outcomes

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Multisystem immune-related adverse events linked with improved survival from immunotherapy in NSCLC

New combination therapy has potential to treat aggressive cancers with common mutations

Study demonstrates safety of novel immuno-oncology therapy in patients with advanced solid tumors

First checkpoint inhibitor vaccine shown to be safe, effective in colon cancer animal model

New model can predict the risk of adverse side effects of cancer treatment

MD Anderson presents positive clinical data from combination cancer therapies at SITC 2020

High dose radiation therapy linked to shorter survival times in NSCLC patients

Study finds persistence of racial disparities in treatment for common lung cancer

New tool can provide non-invasive decision support for NSCLC treatment

New study may lead to more effective, personalized cancer immunotherapies

New initiative identifies key parameters underlying effective anti-tumor immunity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News